Castle Biosciences to Present New Data on DecisionDx-SCC Test at ASTRO 2023 Annual Meeting

Castle Biosciences, a leading diagnostics company, is set to share new data on its DecisionDx-SCC test at the American Society for Radiation Oncology (ASTRO) 2023 Annual Meeting in San Diego. The study, led by Dr. Jason Newman from the Medical University of South Carolina, aims to demonstrate the test’s ability to identify node-negative cutaneous squamous cell carcinoma (SCC) patients at a higher risk of metastasis who may benefit from adjuvant radiation therapy (ART).

The DecisionDx-SCC test is a 40-gene expression profile that provides independent and objective information on a patient’s biologic risk of metastasis. By complementing traditional risk stratification methods, the test can guide risk-aligned treatment decisions, such as considering radiation therapy for a patient. The study found that DecisionDx-SCC significantly stratified the cohort according to the risk of metastasis, with different metastasis-free survival rates for patients with Class 1 (low risk), Class 2A (moderate risk), and Class 2B (high risk) test results.

The data presented at the ASTRO meeting will highlight the potential of DecisionDx-SCC test results in refining the selection of node-negative SCC patients who are most likely to benefit from adjuvant radiation therapy. This information can be invaluable in guiding treatment decisions and potentially de-intensifying treatment for low-risk patients while considering adjuvant therapy for those with a higher risk of metastasis.

Castle Biosciences is committed to improving health through innovative tests that guide patient care. In addition to the DecisionDx-SCC test, the company offers tests for skin cancers, uveal melanoma, Barrett’s esophagus, and mental health conditions. They also have ongoing research and development programs for tests in other diseases with high clinical need.

The abstracts from the presentation will be published in the International Journal of Radiation Oncology • Biology • Physics (Red Journal). Castle Biosciences continues to prioritize patients, clinicians, employees, and investors in its mission to transform disease management.

For more information about Castle Biosciences and its tests, please visit www.CastleBiosciences.com and connect with them on LinkedIn, Facebook, and Instagram.